FindTrial
Sign In

VS-7375

DRUG4 trials

Sponsors

Verastem, Inc.

Conditions

Colorectal CancerG12D Mutated KRASNon Small Cell Lung CancerNon-Small Cell Lung CancerPancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)Solid Tumor, Adult

Phase 1

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingNCT07020221
Verastem, Inc.Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer +2
Start: 2025-06-24End: 2028-12-01Target: 295Updated: 2026-04-22

Phase 2

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
RecruitingNCT07644559
Verastem, Inc.Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Start: 2026-06-16End: 2028-12-01Target: 180Updated: 2026-09-03
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
RecruitingNCT07659795
Verastem, Inc.Colorectal Cancer
Start: 2026-07-28End: 2028-12-01Target: 150Updated: 2026-09-08
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
RecruitingNCT07659782
Verastem, Inc.Non-Small Cell Lung Cancer
Start: 2026-07-22End: 2028-12-01Target: 105Updated: 2026-09-10

Related Papers

Abstract 7100: VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a single agent and in combination with other agents
Cancer Research2026-04-03
Abstract PR007: Anti-tumor efficacy of the selective oral KRAS G12D dual ON/OFF inhibitor VS-7375 as a single agent and in combination with targeted agents
Cancer Research2026-03-05
Abstract A076: VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with superior anti-tumor efficacy relative to ON-only KRAS inhibitors
Molecular Cancer Therapeutics2025-10-22